Triple-drug, fixed-dose combinations for the treatment of hypertension: Focus on olmesartan/amlodipine/hydrochlorothiazide combination

Drugs of Today

Volumn 47, Issue 3, 2011, Pages 197-206

  Chrysant, Steven G ^a  

^a Oklahoma Cardiovascular and Hypertension Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; AMLODIPINE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; OLMESARTAN; RESERPINE; VALSARTAN; ANTIHYPERTENSIVE AGENT; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

COMBINATION CHEMOTHERAPY; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; REVIEW; SYSTOLIC BLOOD PRESSURE; CLINICAL TRIAL (TOPIC); DRUG COMBINATION;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; TETRAZOLES;

EID: 80051929597     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.3.1587028     Document Type: Review

References (37)

1. Chobanian, A.V., Bakris, G.L., Black, H.R. et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42(6): 1206-52.
2. Mancia, G., De Backer, G., Dominiczak, A. et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007, 25(9): 1751-62.
3. Chrysant, S.G. Stopping the cardiovascular disease continuum: Focus on prevention. World J Cardiol 2010, 2(3): 43-9.
4. Kearney, P.M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P.K., He, J. Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365(9455): 217-23.
5. Roger, V.L., Go, A.S., Lloyd-Jones, D.M. et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011, 123(4): e18-e209.
6. Egan, B.M., Zhao, Y., Axon, R.N. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010, 303(20): 2043-50.
7. Lewington, S., Clarke, R., Qizilbash, N., Peto, R., Collins, R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360(9349):1903-13.
8. Staessen, J.A., Li, Y., Thijs, L., Wang, J.G. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res 2005, 28(5): 385-407.
9. Okonofua, E.C., Simpson, K.N., Jesri, A., Rehman, S.U., Durkalski, V.L., Egan, B.M. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 2006, 47(3): 345-51.
10. Nesbitt, S.D. Overcoming therapeutic inertia in patients with hypertension. Postgrad Med 2010, 122(1): 118-24.
11. Kravitz, R.L., Hays, R.D., Sherbourne, C.D., DiMatteo, M.R., Rogers, W.H., Ordway, L., Greenfield, S. Recall of recommendations and adherence to advice among patients with chronic medical conditions. Arch Intern Med 1993, 153(16): 1869-78.
12. Yiannakopoulou, E., Papadopulos, J.S., Cokkinos, D.V., Mountokalakis, T.D. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005, 12(3): 243-9.
13. Chapman, R.H., Benner, J.S., Petrilla, A.A., Tierce, J.C., Collins, S.R., Battleman, D.S., Schwartz, J.S. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005, 165(10): 1147-52.
14. Osterberg, L., Blaschke, T. Adherence to medication. N Engl J Med 2005, 353(5): 487-97.
15. Taylor, A.A., Shoheiber, O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail 2003, 9(6): 324-32.
16. Bangalore, S., Kamalakkannan, G., Parkar, S., Messerli, F.H. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007, 120(8): 713-9.
17. Chrysant, S.G. Using fixed-dose combination therapies to achieve blood pressure goals. Clin Drug Investig 2008, 28(11): 713-34.
18. Ausubel, H., Levine, M.L. Treatment of hypertension with Ser-Ap-Es. Curr Ther Res Clin Exp 1967, 9(1): 29-35.
19. Moser, M. From JNC I to JNC 7 - what have we learned? Prog Cardiovasc Dis 2006, 48(5): 303-15.
20. Fagan, T.C. Remembering the lessons of basic pharmacology. Arch Intern Med 1994, 154(13): 1430-1.
21. Epstein, M., Bakris, G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med 1996, 156(17): 1969-78.
22. Burnier, M., Brown, R.E., Ong, S.H., Keskinaslan, A., Khan, Z.M. Issues in blood pressure control and the potential role of single-pill combination therapies. Int J Clin Pract 2009, 63(5): 790-8.
23. Calhoun, D.A., Lacourciere, Y., Chiang, Y.T., Glazer, R.D. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension 2009, 54(1): 32-9.
24. Destro, M., Luckow, A., Samson, M., Kandra, A., Brunel, P. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS Study. J Am Soc Hypertens 2008, 2(4): 294-302.
25. Chrysant, S.G., Oparil, S., Melino, M., Karki, S., Lee, J., Heyrman, R. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens (Greenwich) 2009, 11(9): 475-82.
26. Oparil, S., Melino, M., Lee, J., Fernandez, V., Heyrman, R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther 2010, 32(7): 1252-69.
27. Volpe, M., Miele, C., Haag, U. Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin Drug Investig 2009, 29(6): 381-91.
28. Chrysant, S.G., Melino, M., Karki, S., Lee, J., Heyrman, R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008, 30(4): 587-604.
29. Oparil, S., Chrysant, S.G., Melino, M., Lee, J., Karki, S., Heyrman, R. Long-term efficacy of a combination of amlodipine and olmesartan medoxomil +/- hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial. J Hum Hypertens 2010, 24(12): 831-8.
30. Lacourcière, Y., Taddei, S., Konis, G. et al. Aliskiren/ amlodipine/hydrochlorothiazide, triple combination provides - 49.53/-22.53mmHg MSSBP/MSDBP reduction in patients with severe hypertension (baseline MSSBP 180 - < 200mmHg). Hypertension [High Blood Press Res Sci Sess (Oct 13-16, Washington, D.C.) 2010] 2010, 56(5): e134.
31. Lacourcière, Y., Taddei, S., Konis, G. et al. Aliskiren/ amlodipine/ hydrochlorothiazide provides significant blood pressure reductions in patients with very severe hypertension (systolic BP ≥190mmHg - < 200mmHg). Hypertension [High Blood Press Res Sci Sess (Oct 13-16, Washington, D.C.) 2010] 2010, 56(5): e134.
32. Rosendorff, C., Black, H.R., Cannon, C.P. et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007, 115(21): 2761-88.
33. Kalaitzidis, R., Bakris, G.L. Lower blood pressure goals for cardiovascular and renal risk reduction: are they defensible? J Clin Hypertens (Greenwich) 2009, 11(7): 345-7.
34. Julius, S., Kjeldsen, S.E., Weber, M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363(9426): 2022-31.
35. Staessen, J.A., Thijisq, L., Fagard, R. et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004, 22(4): 847-57.
36. Gradman, A.H. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich) 2010, 12(11): 869-78.
37. Calhoun, D.A., Jones, D., Textor, S. et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008, 117(25): e510-26.